171 related articles for article (PubMed ID: 29190574)
1. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
[TBL] [Abstract][Full Text] [Related]
2. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J
Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
[TBL] [Abstract][Full Text] [Related]
4. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
5. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
6. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod (Gilenya) and melanoma.
Robinson CL; Guo M
BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 28003234
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous CD30
Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
[No Abstract] [Full Text] [Related]
10. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
[TBL] [Abstract][Full Text] [Related]
11. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
Ueda N; Saida K
BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
[TBL] [Abstract][Full Text] [Related]
12. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
13. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
Artemiadis AK; Nikolaou G; Kolokythopoulos D; Tegos N; Terentiou A; Triantafyllou N; Papanastasiou I
Mult Scler; 2015 May; 21(6):795-6. PubMed ID: 25432949
[No Abstract] [Full Text] [Related]
14. Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.
Forrestel AK; Modi BG; Longworth S; Wilck MB; Micheletti RG
JAMA Neurol; 2016 Mar; 73(3):355-6. PubMed ID: 26751160
[No Abstract] [Full Text] [Related]
15. Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.
Cheraghmakani H; Nasehi MM; Baghbanian SM
Mult Scler Relat Disord; 2019 Aug; 33():116-120. PubMed ID: 31185372
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
Thoo S; Cugati S; Lee A; Chen C
Mult Scler; 2015 Feb; 21(2):249-51. PubMed ID: 24696055
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.
Morillos MB; de Aguiar PHP; Franceschini PR; Duarte JÁ; Piccini CD; Finkelsztejn A
Neurol Sci; 2023 Jan; 44(1):361-363. PubMed ID: 36031684
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
19. Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Matoula T; Nikolaou V; Marinos L; Katsavos S; Nasis G; Economidi A; Karampidou K; Stratigos A; Antoniou C
Mult Scler; 2016 Oct; 22(12):1630-1631. PubMed ID: 27053634
[No Abstract] [Full Text] [Related]
20. Persistent headache in patients with multiple sclerosis starting treatment with fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MV; Matta AP; Mendes MF; Siquineli F
Headache; 2015 Apr; 55(4):578-9. PubMed ID: 25754576
[No Abstract] [Full Text] [Related]
[Next] [New Search]